On the public citation graph
Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease
0 signed · 94 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archderm.132.2.184openalex-snapshot
Methotrexate Osteopathy in Long-term, Low-Dose Methotrexate Treatment for Psoriasis and Rheumatoid Arthritis
inferredcites →https://doi.org/10.1002/1529-0131(200003)43:3<522::aid-anr7>3.0.co;2-yopenalex-snapshot
Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County rheumatoid arthritis register
inferredcites →https://doi.org/10.1002/9780470623992.ch59openalex-snapshot
Chapter 59. Inflammation‐Induced Bone Loss in the Rheumatic Diseases
inferredcites →https://doi.org/10.1002/acr.20172openalex-snapshot
Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis
inferredcites →https://doi.org/10.1002/art.1780390317openalex-snapshot
The effect of methotrexate on mouse bone cells in culture
inferredcites →https://doi.org/10.1002/art.20383openalex-snapshot
Bisphosphonates: Environmental protection for the joint?
inferredcites →https://doi.org/10.1002/art.20384openalex-snapshot
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor–mediated arthritis
inferredcites →https://doi.org/10.1002/art.21293openalex-snapshot
Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?
inferredcites →https://doi.org/10.1002/art.21824openalex-snapshot
Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis
inferredcites →https://doi.org/10.1002/art.21896openalex-snapshot
The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction
inferredcites →https://doi.org/10.1002/art.23417openalex-snapshot
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial
inferredcites →https://doi.org/10.1002/art.23988openalex-snapshot
Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: A prospective randomized clinical trial
inferredcites →https://doi.org/10.1002/art.24879openalex-snapshot
Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial
inferredcites →https://doi.org/10.1002/jbmr.1489openalex-snapshot
Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: A population-based cohort study
inferredcites →https://doi.org/10.1002/jor.20145openalex-snapshot
Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge
inferredcites →https://doi.org/10.1007/bf02207677openalex-snapshot
Osteoporosis in rheumatoid arthritis: Effect of disease activity
inferredcites →https://doi.org/10.1007/s00198-005-0037-2openalex-snapshot
Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial
inferredcites →https://doi.org/10.1007/s00198-008-0805-xopenalex-snapshot
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study
inferredcites →https://doi.org/10.1007/s00198-010-1326-yopenalex-snapshot
Do RANKL inhibitors (denosumab) affect inflammation and immunity?
inferredcites →https://doi.org/10.1007/s001980050189openalex-snapshot
Bone Mass Change During Methotrexate Treatment in Patients with Juvenile Rheumatoid Arthritis
inferredcites →https://doi.org/10.1007/s00223-006-0060-0openalex-snapshot
Methotrexate, Azathioprine, Cyclosporine, and Risk of Fracture
inferredcites →https://doi.org/10.1007/s002230020039openalex-snapshot
In Vitro Effects of Chemotherapeutic Agents on Human Osteoblast-like cells
inferredcites →https://doi.org/10.1007/s002239900585openalex-snapshot
Effects of Long-Term Administration of Methotrexate on Bone Mineral Density in Rheumatoid Arthritis
inferredcites →https://doi.org/10.1007/s00296-003-0298-zopenalex-snapshot
The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis
inferredcites →https://doi.org/10.1007/s002960000080openalex-snapshot
Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids
inferredcites →https://doi.org/10.1007/s10067-009-1363-0openalex-snapshot
Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis
inferredcites →https://doi.org/10.1016/0002-9343(94)90131-7openalex-snapshot
Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events
inferredcites →https://doi.org/10.1016/8756-3282(94)00032-uopenalex-snapshot
The short- and long-term effects of methotrexate on the rat skeleton
inferredcites →https://doi.org/10.1016/j.bone.2008.09.014openalex-snapshot
Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment
inferredcites →https://doi.org/10.1016/j.rdc.2011.07.003openalex-snapshot
Update on Glucocorticoid-Induced Osteoporosis
inferredcites →https://doi.org/10.1016/s0002-9440(10)63144-6openalex-snapshot
Repair of Local Bone Erosions and Reversal of Systemic Bone Loss Upon Therapy with Anti-Tumor Necrosis Factor in Combination with Osteoprotegerin or Parathyroid Hormone in Tumor Necrosis Factor-Mediated Arthritis
inferredcites →https://doi.org/10.1016/s0140-6736(09)60250-6openalex-snapshot
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(88)90185-7openalex-snapshot
CORRELATION OF PLASMA INTERLEUKIN 1 LEVELS WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS
inferredcites →https://doi.org/10.1038/nm1538openalex-snapshot
Dickkopf-1 is a master regulator of joint remodeling
inferredcites →https://doi.org/10.1038/nrrheum.2010.5openalex-snapshot
Methotrexate—how does it really work?
inferredcites →https://doi.org/10.1038/sj.leu.2404556openalex-snapshot
Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells
inferredcites →https://doi.org/10.1056/nejmc073408openalex-snapshot
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
inferredcites →https://doi.org/10.1056/nejmoa032534openalex-snapshot
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis
inferredcites →https://doi.org/10.1056/nejmoa071408openalex-snapshot
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
inferredcites →https://doi.org/10.1056/nejmoa0802633openalex-snapshot
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
inferredcites →https://doi.org/10.1056/nejmoa0809493openalex-snapshot
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
inferredcites →https://doi.org/10.1080/00365520500206467openalex-snapshot
Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease
inferredcites →https://doi.org/10.1080/03009749950155355openalex-snapshot
Bone mineral density of the lumbar spine in patients with advanced rheumatoid arthritis: Influence of functional capacity and corticosteroid use
inferredcites →https://doi.org/10.1093/rheumatology/35.4.309openalex-snapshot
BONE MASS MEASUREMENT AND BONE METABOLISM IN RHEUMATOID ARTHRITIS: A REVIEW
inferredcites →https://doi.org/10.1093/rheumatology/35.4.342openalex-snapshot
IN VITRO EFFECTS OF METHOTREXATE ON HUMAN ARTICULAR CARTILAGE AND BONE-DERIVED OSTEOBLASTS
inferredcites →https://doi.org/10.1093/rheumatology/41.7.741openalex-snapshot
Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density
inferredcites →https://doi.org/10.1093/rheumatology/keh592openalex-snapshot
Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1093/rheumatology/kei082openalex-snapshot
Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study
inferredcites →https://doi.org/10.1093/rheumatology/keq123openalex-snapshot
Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis
inferredcites →https://doi.org/10.1097/01.bor.0000166383.73153.cfopenalex-snapshot
New perspectives on parathyroid hormone therapy
inferredcites →https://doi.org/10.1097/bor.0b013e3283373fa0openalex-snapshot
Actual status of antiinterleukin-1 therapies in rheumatic diseases
inferredcites →https://doi.org/10.1111/j.1572-0241.2005.50219.xopenalex-snapshot
Maintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's Disease
inferredcites →https://doi.org/10.1136/ard.2004.028670openalex-snapshot
Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment
inferredcites →https://doi.org/10.1136/ard.2005.044198openalex-snapshot
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis
inferredcites →https://doi.org/10.1136/ard.2007.073817openalex-snapshot
Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis
inferredcites →https://doi.org/10.1136/ard.2007.076604openalex-snapshot
Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis
inferredcites →https://doi.org/10.1136/ard.2007.084426openalex-snapshot
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
inferredcites →https://doi.org/10.1136/ard.2008.091611openalex-snapshot
Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss
inferredcites →https://doi.org/10.1136/ard.2008.092866openalex-snapshot
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
inferredcites →https://doi.org/10.1136/ard.2008.106484openalex-snapshot
Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study
inferredcites →https://doi.org/10.1136/ard.2009.127787openalex-snapshot
Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis
inferredcites →https://doi.org/10.1136/ard.52.8.582openalex-snapshot
Methotrexate osteopathy in rheumatic disease.
inferredcites →https://doi.org/10.1136/ard.53.1.18openalex-snapshot
Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis–a population based study.
inferredcites →https://doi.org/10.1136/ard.60.8.736openalex-snapshot
Stress fracture in long term methotrexate treatment for psoriatic arthritis
inferredcites →https://doi.org/10.1136/ard.62.10.1020openalex-snapshot
Bone mineral density improvement in spondyloarthropathy after treatment with etanercept
inferredcites →https://doi.org/10.1136/ard.62.4.347openalex-snapshot
Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α
inferredcites →https://doi.org/10.1155/2007/216162openalex-snapshot
Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease Patients
inferredcites →https://doi.org/10.1172/jci200422087openalex-snapshot
An amino-bisphosphonate targets MMP-9–expressing macrophages and angiogenesis to impair cervical carcinogenesis
inferredcites →https://doi.org/10.1186/1749-799x-4-17openalex-snapshot
The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study
inferredcites →https://doi.org/10.1186/ar2219openalex-snapshot
A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab
inferredcites →https://doi.org/10.1196/annals.1346.055openalex-snapshot
The Effect of Anti‐TNF‐α Therapy on Spinal Bone Mineral Density in Patients with Crohn's Disease
inferredcites →https://doi.org/10.1196/annals.1351.040openalex-snapshot
Bone Metabolism Changes During Anti‐TNF‐α Therapy in Patients with Active Rheumatoid Arthritis
inferredcites →https://doi.org/10.1359/jbmr.090731openalex-snapshot
Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures
inferredcites →https://doi.org/10.1517/14656560903071043openalex-snapshot
Therapeutic options for rheumatoid arthritis
inferredcites →https://doi.org/10.2106/00004623-198466040-00016openalex-snapshot
Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model.
inferredcites →https://doi.org/10.2106/jbjs.g.01443openalex-snapshot
Stimulation of Fracture-Healing with Systemic Intermittent Parathyroid Hormone Treatment
inferredcites →https://doi.org/10.2106/jbjs.h.01774openalex-snapshot
Bilateral Low-Energy Simultaneous or Sequential Femoral Fractures in Patients on Long-Term Alendronate Therapy
inferredcites →https://doi.org/10.2106/jbjs.j.01379openalex-snapshot
Parathyroid Hormone 1-84 Accelerates Fracture-Healing in Pubic Bones of Elderly Osteoporotic Women
inferredcites →https://doi.org/10.3899/jrheum.100829openalex-snapshot
Relationship of Focal Erosions, Bone Mineral Density, and Parathyroid Hormone in Rheumatoid Arthritis
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4058421openalex-extracted
Association between Biologic Therapy and Fracture Incidence in Patients with Selected Rheumatic and Autoimmune Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1007/978-3-642-36569-0_243openalex-snapshot
Nanotechnology in Sports Medicine
inferred← citeshttps://doi.org/10.1007/978-3-642-36801-1_243-1openalex-snapshot
Nanotechnology in Sports Medicine
inferred← citeshttps://doi.org/10.1007/s00198-021-05824-7openalex-snapshot
Vertebral fractures are increased in rheumatoid arthritis despite recent therapeutic advances: a case-control study
inferred← citeshttps://doi.org/10.1007/s00223-020-00765-5openalex-snapshot
Clinical and Radiological Characterization of Patients with Immobilizing and Progressive Stress Fractures in Methotrexate Osteopathy
inferred← citeshttps://doi.org/10.1007/s12020-012-9813-xopenalex-snapshot
Osteoporosis in chronic inflammatory disease: the role of malnutrition
inferred← citeshttps://doi.org/10.1016/j.autrev.2017.01.014openalex-snapshot
Effects of targeted therapies on the bone in arthritides
inferred← citeshttps://doi.org/10.1016/j.berh.2026.102151openalex-snapshot
Management of glucocorticoid-induced osteoporosis in rheumatic diseases
inferred← citeshttps://doi.org/10.1016/j.phrs.2022.106278openalex-snapshot
Association between biologic therapy and fracture incidence in patients with selected rheumatic and autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2014.05.008openalex-snapshot
Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1136/annrheumdis-2020-218856openalex-snapshot
Correspondence on ‘Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study‘
inferred← citeshttps://doi.org/10.1155/2013/945945openalex-snapshot
Bone Effects of Biologic Drugs in Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.3389/fphar.2025.1522937openalex-snapshot
Osteoporosis diagnosis and ingredients of prescription medications: a population-based study
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.